Jump to main content
Jump to site search

Issue 3, 2010
Previous Article Next Article

Boronic acids in medicinal chemistry: anticancer, antibacterial and antiviral applications

Author affiliations

Abstract

In 2003, bortezomib, a first-in-class therapeutic, gained approval from the US Federal Drug Administration for the treatment of relapsed multiple myeloma and mantle cell lymphoma. Approval in the UK, for multiple myeloma, followed in 2006. Bortezomib contains a boronic acid, a functional group that has become increasingly more commonplace within the medicinal chemistry literature. The introduction of this drug has sparked a renewed interest in the investigation of boronic acids as drugs for a wide range of diseases. This review will guide the reader through the most recent developments in this field, by considering in turn, the biological target's amenable to the action of boronic acids.

Graphical abstract: Boronic acids in medicinal chemistry: anticancer, antibacterial and antiviral applications

Back to tab navigation

Publication details

The article was received on 20 Jul 2010, accepted on 20 Jul 2010 and first published on 20 Aug 2010


Article type: Review Article
DOI: 10.1039/C0MD00119H
Citation: Med. Chem. Commun., 2010,1, 183-198
  •   Request permissions

    Boronic acids in medicinal chemistry: anticancer, antibacterial and antiviral applications

    P. C. Trippier and C. McGuigan, Med. Chem. Commun., 2010, 1, 183
    DOI: 10.1039/C0MD00119H

Search articles by author

Spotlight

Advertisements